Generon Initiates a Phase I Clinical Study for F-652 in Australia
03:30 EDT 6 Sep 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Generon (Shanghai) Corporation Ltd. today announced the initiation of a
Phase I clinical trial for F-652 in Australia. F-652 is a recombinant
protein containing a human interleukin-22 (IL-22) dimer. The current
Phase I study is ...
Other Sources for this Article
Generon (Shanghai) Corporation Ltd.
Feng Li, +86 21 5132-0626 ext.
8029
Vice President Business Development
info@generionbiomed.com
More From BioPortfolio on "Generon Initiates a Phase I Clinical Study for F-652 in Australia"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
